Does surgery induce angiogenesis in dormant breast cancer?

September 12, 2005

Analysis of breast-cancer relapse patterns from two independent databases provides indirect evidence for the theory that surgery to remove the primary tumor may initiate formation of a new blood supply (angiogenesis) in formerly dormant metastases, accounting for a pattern of early relapse in younger women.

The study, published online by the INTERNATIONAL JOURNAL OF SURGERY, analyzed data from 1,173 women in three clinical trials who had surgery for breast cancer, but no further treatment. The researchers found two relapse peaks: one at 18 months, and another 5 years. Closer analysis showed that 20 percent of premenopausal, node-positive patients (whose cancer had spread to the lymph nodes) relapsed within the first 10 months after removal of the primary tumor.

The researchers, led by Michael Retsky, PhD, an investigator in the Vascular Biology Program at Children's Hospital Boston, believe their observations may help to explain the so-called "mammography paradox" among women aged 40 to 49: a counterintuitive temporary excess in mortality for the screened population compared to controls. Calculations based on their data predict that surgery-induced angiogenesis would accelerate disease by a median of two years and produce 0.11 early deaths per 1000 screened young women in the third year of screening. The predicted timing, as well as the magnitude of excess mortality, agree with the actual trial data and relapse patterns.

Although the study did not look at biological mechanisms of relapse, primary tumors have been shown to secrete angiogenesis inhibitors, which naturally inhibit the growth of metastases, so surgery to remove the primary tumor might eliminate this inhibition. Alternatively, surgery might spur release of angiogenesis promoters through a wound-healing mechanism.

"Cancer outgrowth after surgery has been observed for over 100 years, and the mechanisms have not been fully identified," comments Retsky. "Our analysis suggests that biology may be the underlying cause, rather than something going wrong during surgery. It also suggests that while most young women benefit from early detection of breast cancer, a small percentage will relapse and die early of metastatic disease. The paper suggests remedial steps that might prevent the sudden growth from occurring.

"The results of this study could also be considered when designing treatment protocols for young women with positive nodes, since it may not be a coincidence that adjuvant chemotherapy works best for those patients," he adds. "Young women need to be advised of the risk of accelerated tumor growth and early relapse before giving informed consent for mammography."

Coauthors include Romano Demicheli, MD, PhD of Milan, Italy and William Hrushesky, MD of Colombia, SC.
For further information and copies of the full paper please e-mail: or telephone +44 (0) 207 754 5402. Full text of the article can be found at

Children's Hospital Boston is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 500 scientists, including eight members of the National Academy of Sciences, nine members of the Institute of Medicine and 10 members of the Howard Hughes Medical Institute comprise Children's research community. Founded as a 20-bed hospital for children, Children's Hospital Boston today is a 347-bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Children's also is the primary pediatric teaching affiliate of Harvard Medical School. For more information about the hospital and its research visit:

Boston Children's Hospital

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to